A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers

Diabetes Mellitus, Type II Clinical Trial

Official title:

A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02565368
• Other study ID #: 158BE15008
• Status: Completed
• Phase: Phase 1
• First received: September 23, 2015
• Last updated: September 30, 2015
• Start date: July 2015
• Est. completion date: August 2015

Study information

• Verified date: September 2015
• Source: Chong Kun Dang Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Korea: Ministry of Food and Drug Safety
• Study type: Interventional

Clinical Trial Summary

This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.5/1000 mg in healthy male volunteers.

Description:

To healthy male subjects of twenty six(26), following treatments are administered dosing in each period fed condition(high fat meals) and wash-out period is a minimum of 7 days.

Treatment A(Reference Drug): DuvieTM Tab. 0.5mg 1T + Glicophage XR Tab. 1000mg 1T Treatment B(Test Drug): CKD-395 0.5/1000mg Tab. 1T Pharmacokinetic blood samples are collected up to 48hrs. Safety and pharmacokinetic are assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Healthy man older than 19 years at the time of screening.

2. BMI more than 17.5kg/m2 and less than 30.5kg/m2 and weight more than 55kg

3. Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination.

4. Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as ECG test.

5. Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital IRB.

6. Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures.

Exclusion Criteria:

1. Subjects who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)

2. Subjects who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.

3. Subjects who show AST or AST > 2 times upper limit of normal range.

4. Subjects who drink Alcohol > 210g/week within 6 months prior to the screening.

5. Subjects who take the medication involved in other clinical trials or bioequivalence tests within three months before the first dose medication characters.

6. Subjects who show Systolic Blood Pressure = 140 mmHg or Diastolic Blood Pressure = 90 mmHg at screening.

7. Subjects who have history of alcohol or drug abuse, within 1 year

8. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.

9. Smoker ( = 20cigarettes/day)

10. Subjects who takes ETC or OTC medicine within 10days before the first IP administration.

11. Subjects who do the whole blood donation within two months or component blood donation within 1month prior to the first dosing.

12. Subjects who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.

13. Patients with hypersensitivity to lobeglitazone or any other thiazolidinediones ( Rosiglitazone, Rioglitazone) and to Metformin or any other biguanides

14. Patients with severe heart failure or congestive heart failure of needing drug therapy

15. Patients with liver disease

16. Patients with severe renal disease

17. Patients with diabetes mellitus with ketoacidosis, diabetes coma and prior

18. Patients before or after surgery, with severe infections, severe trauma

19. Subjects with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

20. Patients with renal disease or renal failure caused by cardiovascular collapse, acute myocardial infarction, sepsis (Serum creatinine = 1.5mg/dL or abnormal creatinie clearance)

21. Patients who had a test to injecting radioactive iodine in vein

22. Patients with severe infections or severe traumatic whole body injuries

23. Patients with undernourishment condition or starvation state or hyposthenia or hypopituitarism, or hypoadrenalism

24. Patients with respiratory failure, or stomach disease

25. Subjects who is not able to intake high fat meals

26. Subjects who is not able to comply with guidelines described in the protocol.

27. Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Diabetes Mellitus, Type II

Intervention

Drug:
• Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg
single oral administration
• CKD-395 0.5/1000mg
single oral administration

Locations

Country	Name	City	State
Korea, Republic of	Chonbuk National University Hospital	Jeonju-si	Jeollabuk-do

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUClast of Lobeglitazon and metformin		Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs / Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs	No
Primary	Cmax of Lobeglitazon and metformin		Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs / Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs	No
Secondary	AUCinf of Lobeglitazon and metformin		Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs / Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs	No
Secondary	Tmax of Lobeglitazon and metformin		Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs / Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs	No
Secondary	t1/2 of Lobeglitazon and metformin		Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs / Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs	No
Secondary	CL/F of Lobeglitazon and metformin		Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs / Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs	No
Secondary	Vd/F of Lobeglitazon and metformin		Lobeglitazone: 0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs / Metformin: 0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 and 48hrs	No